Capula Management Ltd Purchases New Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Capula Management Ltd bought a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 6,396 shares of the company's stock, valued at approximately $354,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. JPMorgan Chase & Co. lifted its stake in Tarsus Pharmaceuticals by 2,088.8% during the third quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company's stock valued at $14,477,000 after buying an additional 420,057 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of Tarsus Pharmaceuticals by 14.8% during the fourth quarter. Jennison Associates LLC now owns 2,500,132 shares of the company's stock valued at $138,432,000 after acquiring an additional 321,552 shares during the period. Verition Fund Management LLC purchased a new stake in shares of Tarsus Pharmaceuticals in the 3rd quarter valued at approximately $763,000. Barclays PLC boosted its stake in Tarsus Pharmaceuticals by 345.9% in the 3rd quarter. Barclays PLC now owns 98,663 shares of the company's stock worth $3,246,000 after purchasing an additional 76,538 shares during the period. Finally, Wellington Management Group LLP grew its position in Tarsus Pharmaceuticals by 14.2% during the 3rd quarter. Wellington Management Group LLP now owns 145,347 shares of the company's stock worth $4,780,000 after purchasing an additional 18,019 shares in the last quarter. Institutional investors and hedge funds own 90.01% of the company's stock.

Tarsus Pharmaceuticals Stock Up 5.2 %

TARS stock traded up $2.31 during trading hours on Friday, hitting $46.43. The company's stock had a trading volume of 781,138 shares, compared to its average volume of 682,663. The stock has a 50 day moving average price of $48.17 and a two-hundred day moving average price of $47.32. Tarsus Pharmaceuticals, Inc. has a 12 month low of $20.08 and a 12 month high of $57.28. The company has a market capitalization of $1.78 billion, a PE ratio of -12.19 and a beta of 0.94. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Remove Ads

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The firm had revenue of $66.41 million during the quarter, compared to analysts' expectations of $58.80 million. On average, equities research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Insider Activity

In other news, insider Dianne C. Whitfield sold 2,137 shares of the business's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total value of $107,085.07. Following the completion of the sale, the insider now directly owns 46,355 shares in the company, valued at approximately $2,322,849.05. The trade was a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Bobak R. Azamian sold 7,131 shares of the firm's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $330,093.99. Following the completion of the transaction, the chief executive officer now owns 70,720 shares in the company, valued at $3,273,628.80. The trade was a 9.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,542 shares of company stock valued at $1,581,173. Insiders own 8.25% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on TARS shares. Barclays reduced their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Oppenheimer increased their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 22nd. Jefferies Financial Group lifted their target price on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. HC Wainwright reissued a "buy" rating and issued a $73.00 price target on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Finally, Guggenheim reaffirmed a "buy" rating and set a $78.00 price objective (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $63.67.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.